Narrow your search

Library

LUCA School of Arts (2)

Odisee (2)

Thomas More Kempen (2)

Thomas More Mechelen (2)

UCLL (2)

ULiège (2)

VDIC (2)

VIVES (2)

KBR (1)

KU Leuven (1)

More...

Resource type

book (5)


Language

English (5)


Year
From To Submit

2009 (1)

2002 (1)

1991 (1)

1983 (1)

1977 (1)

Listing 1 - 5 of 5
Sort by

Book
Fragile X--cancer cytogenetics : proceedings of the 1989 Albany birth defects symposium XX, held in Albany, New York, October 16-17, 1989
Authors: ---
ISBN: 0471560987 Year: 1991 Publisher: New York Toronto Singapore Wiley-Liss

Loading...
Export citation

Choose an application

Bookmark

Abstract

The molecular biology of the mammalian genetic apparatus
Authors: --- ---
ISBN: 0720406269 0720406250 9780720406252 9780720406269 Year: 1977 Publisher: Amsterdam : North Holland Publishing Company,

Cancer and the environment
Authors: ---
ISBN: 030908475X 9786610183517 1280183519 0309505062 9780309505062 9780309084758 030508475X 0309169240 Year: 2002 Publisher: Washington, D.C. (2101 Constitution Ave., N.W. Washington, DC 20418) National Academy Press


Book
Cancer prevention.
Authors: --- --- ---
ISBN: 3540692967 9786611913830 1281913839 3540692975 Year: 2009 Publisher: Berlin ; London : Springer,

Loading...
Export citation

Choose an application

Bookmark

Abstract

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.

Listing 1 - 5 of 5
Sort by